How should Journavx (suzetrigine) be used for postoperative pain management compared to opioids?

Journavx (Suzetrigine) for Postoperative Pain Management

Journavx should be considered as a first-line non-opioid option for moderate-to-severe acute postoperative pain, particularly for ambulatory procedures like abdominoplasty and bunionectomy, but must be integrated into a multimodal analgesic regimen that includes scheduled acetaminophen and NSAIDs, with opioids reserved for breakthrough pain or more invasive surgeries.

Evidence-Based Positioning

The FDA-approved Journavx (suzetrigine) in 2025 as the first novel non-opioid analgesic in over two decades 1. This selective NaV1.8 sodium channel inhibitor demonstrated statistically significant pain reduction versus placebo in two pivotal Phase 3 trials, with SPID48 scores showing mean differences of 48.4 after abdominoplasty and 29.3 after bunionectomy (both p<0.001) 2. However, neither trial achieved superiority over hydrocodone/acetaminophen 5/325mg, indicating comparable but not superior analgesic efficacy 2.

Clinical Algorithm for Use

When to Choose Journavx Over Opioids:

Primary indications:

• Minimally to moderately painful ambulatory procedures (bunionectomy, abdominoplasty, plastic surgery, orthopedic procedures) 1
• Patients at high risk for opioid-related complications (sleep apnea, substance use history, concurrent benzodiazepine use)
• Patients specifically requesting non-opioid alternatives
• Duration: Up to 14 days of treatment 1

Dosing regimen:

• Initial: 100mg loading dose
• Maintenance: 50mg every 12 hours 1
• Dose reduction required with moderate CYP3A inhibitors 1

When Opioids Remain Preferred:

Current guidelines clearly state that opioids remain first-line therapy for severe acute pain 3. Specifically:

• Severe traumatic injuries (crush injuries, burns)
• Invasive surgeries with expected moderate-to-severe postoperative pain
• When NSAIDs and other therapies are contraindicated 4

The 2022 WSES-GAIS-SIAARTI-AAST guidelines explicitly state: "Opiates are the first-line therapy to treat pain in these patients" for postoperative emergency general surgery 3.

Multimodal Framework

All patients should receive baseline non-opioid therapy regardless of whether Journavx or opioids are used 3, 5:

1. Scheduled (not PRN) acetaminophen: 1000mg every 6 hours
2. Scheduled NSAIDs: Ibuprofen 800mg every 8 hours (staggered with acetaminophen)
3. Regional anesthesia when appropriate 6
4. Add Journavx OR opioids based on pain severity and procedure type

This approach aligns with the 2021 international consensus that "multimodal analgesia should be optimized...to reduce the amount and duration of opioids required" 5.

Safety Profile Comparison

Journavx advantages:

• No addiction potential 2, 7
• Lower nausea/vomiting rates: 9-20% vs 16-33% with hydrocodone/acetaminophen 1
• No respiratory depression risk 7
• No sedation 7

Journavx concerns:

• CPK elevations (2.9% vs 1.2% placebo) - all asymptomatic and resolved without intervention 1
• eGFR decreases ≥25% (2.5% vs 0.9% placebo) - appeared to resolve at follow-up 1
• CYP3A interactions requiring dose adjustments 1
• Contraindicated with strong CYP3A inhibitors 1

Opioid concerns remain substantial:

• Persistent postoperative opioid use: 0.6-26% in opioid-naive patients 8
• 64% increase in all-cause mortality with long-term use 8
• Opioid-induced ventilatory impairment risk 5

Practical Implementation Strategy

For moderate pain (abdominoplasty, bunionectomy, similar procedures):

1. Start scheduled acetaminophen + NSAID immediately postoperatively
2. Add Journavx 100mg loading dose, then 50mg q12h
3. Provide rescue opioids (5-10 tablets maximum) for breakthrough pain only 9
4. Duration: Typically ≤7 days 4, 5

For severe pain (major trauma, extensive surgery):

1. Start scheduled acetaminophen + NSAID
2. Use immediate-release opioids as primary analgesic (PCA if appropriate) 3
3. Consider adding Journavx as opioid-sparing adjunct (though not studied in this context)
4. Avoid long-acting opioids 5

Critical Prescribing Principles

Regardless of agent chosen:

• Prescribe "as needed" rather than scheduled dosing to prevent unnecessary exposure 4
• Limit discharge prescriptions to <7 days 5
• Avoid automatic refills - require patient reassessment 5
• Guide therapy by functional outcomes, not pain scores alone 5
• Query prescription drug monitoring programs when available 9
• Provide naloxone when prescribing opioids to high-risk patients 4

Evidence Limitations

Important caveats about Journavx:

• All trials limited to 48 hours (controlled) or 14 days (open-label) 2, 10
• No data for chronic pain management 11
• Efficacy in severe postoperative pain (major surgery) unknown 11
• Long-term safety profile still emerging 12
• One case report of paresthesia noted post-marketing 13

The meta-analysis by 10 confirms significant SPID48 improvement (MD=38.76, p<0.00001) but acknowledges these trials only included abdominoplasty and bunionectomy patients.

Bottom Line

Journavx represents a valuable addition to the postoperative pain armamentarium but does not replace opioids entirely. Use it as a first-line agent for moderate pain from ambulatory procedures within a multimodal regimen. Reserve opioids for severe pain, major surgery, or when Journavx proves inadequate. The 2022 CDC guideline's core principle remains valid: "opioids are not recommended as first-line therapy for many common acute pain conditions" but have "an important role for acute pain related to severe traumatic injuries [and] invasive surgeries" 4. Journavx now provides a legitimate non-opioid alternative for the former category while opioids remain necessary for the latter.